Dawson v. Archambeau

CourtDistrict Court, D. Colorado
DecidedJanuary 13, 2020
Docket1:16-cv-00489
StatusUnknown

This text of Dawson v. Archambeau (Dawson v. Archambeau) is published on Counsel Stack Legal Research, covering District Court, D. Colorado primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dawson v. Archambeau, (D. Colo. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Senior Judge Marcia S. Krieger

Civil Action No. 16-cv-00489-MSK-NYW

JAMES R. DAWSON, Jr.,

Plaintiff,

v.

JEFF ARCHAMBEAU, CEO of Colorado Health Partners; RICK RAEMISCH, Executive Director of the Colorado Department of Corrections; SUSAN TIONA, Chief Medical Officer of the Colorado Department of Corrections; C. IRELAND, FCF Health Providers; D. HIBBS; T. SICOTTE; and R. FRICKEY,

Defendants. ______________________________________________________________________________

OPINION AND ORDER ON REMAND; GRANTING MOTIONS FOR SUMMARY JUDGMENT IN PART ______________________________________________________________________________

THIS MATTER comes before the Court pursuant to the “Order and Judgment” and Mandate issued by the Tenth Circuit Court of Appeals affirming in part and reversing in part the Court’s order granting summary judgment in favor of all defendants and remanding this matter for further consideration (# 202 and # 205).1 FACTS The following facts are undisputed except where noted. They are construed in the light most favorable to Mr. Dawson, and are supplemented as necessary in the court’s analysis.

1 Also pending are the following motions filed by Mr. Dawson: (1) Motion to Set Case for Trial (# 209); (2) motions for appointment of counsel (# 207 and # 208); and (3) Motion for Copy of the Docket (# 210). Mr. Dawson is an inmate in the custody of the Colorado Department of Corrections (“CDOC”) and has been incarcerated since 1992. Mr. Dawson suffers from Hepatitis C. CDOC health care providers first diagnosed Mr. Dawson with Hepatitis C about 25 years ago. Mr. Dawson asserts that his Hepatitis C has progressed over the term of his incarceration and that he is now experiencing symptoms consistent with end-stage liver disease.2 (# 102 at 3-9). During the pertinent times herein, Mr. Dawson was housed at the Fremont Correctional Facility (“FCF”) in Canon City, Colorado. He alleges that various medical providers at the FCF along with CDOC supervisory officials wrongfully denied him treatment for Hepatitis C pursuant to the CDOC’s Clinical Practice Guidelines for the Prevention, Identification and

Treatment of Viral Hepatitis C (“Clinical Standards”) and for his related symptoms. (#102 at 7- 11). Before 2015, CDOC inmates with Hepatitis C received conventional treatment with interferon and anti-viral medications, which treatment was not always successful in eliminating the disease and often had significant side effects. Beginning in 2015, inmates eligible under the CDOC Clinical Standards applicable to treatment of Hepatitis C could receive new drugs that had impressive cure rates of 95-99% and few significant side effects. Such drugs, known by

2 Mr. Dawson did not support his responses to the Defendants’ motions with a formal affidavit or declaration, as required by Fed. R. Civ. P. 56(c)(1)(A). Nevertheless, his filings, including his verified Amended Complaint (# 102), do contain assertions of fact that appear to be made upon his personal knowledge. Because Mr. Dawson’s papers are construed liberally as an unrepresented party, and because he presumably could (and would, if required) be able to reduce the facts of which he has personal knowledge to a sworn affidavit, the Court will treat factual statements clearly within the scope of Mr. Dawson’s personal knowledge as if they were properly asserted through an affidavit as required by Rule 56. See, e.g., Jackson v. Cheyenne Mtn. Conf. Resort, 92 F. Supp. 2d 1118, 1122 n.3 (D. Colo. 2000). brand names such as Harvoni and Epclusa, although more effective, were also very costly. (#179-3 at 2, #102 at 7-10). 2013-2014 As noted, the 2013 CDOC Clinical Standards for treatment for Hepatitis C used “a combination of pegylated interferon and ribavirin to treat Hepatitis C”. (# 141-20 at 14-17). Interferon-based therapy did not cure the virus in all cases, but it was considered to be “helpful to the liver.” (# 141-21 at 8). To be eligible for such treatment, the 2013 Clinical Standards required that 1) an inmate complete an approved drug and alcohol treatment program which was 2) to be followed by a liver biopsy then 3) reviewed for Hepatitis C treatment. (# 141-20 at 7).

Prior to requesting a liver biopsy, CDOC medical providers recorded relevant information on a Hepatitis C Evaluation Worksheet that was submitted to the Infectious Disease (“ID”) Committee for consideration. The ID committee determined whether an inmate was eligible for treatment, and if so, the inmate had a liver biopsy. For treatment, the 2013 Clinical Standards required a finding of stage 3 fibrosis in the liver. Inmates with stage 2 fibrosis were considered on a case by case basis, but inmates with stage 1 fibrosis were not eligible to receive treatment at all. They were to be monitored for progression of the disease. (# 141-20 at 11-14). The 2013 Clinical Standards recommended that periodic screening (annual liver ultrasounds and lab screens every 6 months) of inmates with chronic Hepatitis C and cirrhosis be considered. (#141- 20 at 15).

On November 26, 2013, Mr. Dawson states that he requested Hepatitis C treatment during an appointment with Dr. Ireland, a physician at FCF. He complained of “dark tea colored urine, itching, fatigue, swelling in my stomach, light colored stool, and [an occasional] bitter taste in my mouth” along with “disabling pain.” (# 102 at 12). However, it does not appear that Mr. Dawson described the pain he was experiencing, nor asked for treatment to alleviate it. The treatment notes do not indicate that that question of pain was addressed by either Mr. Dawson or Dr. Ireland. Instead, it appears that both Dr. Ireland and Mr. Dawson viewed the recitation of his symptoms in the context of treatment for Mr. Dawson’s Hepatitis C. Dr. Ireland informed Mr. Dawson that he needed to obtain documentation verifying that he had previously completed drug and alcohol treatment in accordance with the 2013 Clinical Standards.3 Dr. Ireland then scheduled Mr. Dawson to meet with someone from the Mental Health Department to assess his condition and determine his eligibility for Hepatitis C treatment. (# 102 at 12). In January 2014, Mr. Dawson had a follow-up appointment with Ms. Sicotte, a nurse

practitioner at FCF. He told Ms. Sicotte that he had seen Dr. Ireland in November 2013, but had not yet received any treatment for his Hepatitis C. He informed Ms. Sicotte that he was still suffering from all of the previously listed Hepatitis C symptoms, including “disabling pain.” Again, the record does not reflect that Mr. Dawson described his pain nor requested medication to relieve it. Like Dr. Ireland, it appears that Ms. Sicotte understood Mr. Dawson’s description of symptoms to be for the purpose of qualifying for treatment for his underlying Hepatitis C. Ms. Sicotte did not provide any treatment for Mr. Dawson’s pain symptoms, but informed him that he was scheduled to meet with the Mental Health Department to discuss his eligibility to receive Hepatitis C treatment. (# 102 at 12). Several weeks later, on January 29, 2014, Mr. Dawson met with Mr. Frickey, a nurse

practitioner at FCF, to discuss treatment options for his Hepatitis C. Mr. Dawson informed Mr. Frickey about his appointments with Dr. Ireland and Ms. Sicotte and recited his various

3 It does not appear from the record that Mr. Dawson ever provided this documentation to the medical providers. symptoms noting that his acute abdominal pain, was “not improving.” (# 102 at 12). Mr. Dawson states that Mr. Frickey assured him that he would be receiving Hepatitis C treatment, however, Mr. Frickey states that after advising Mr. Dawson of the risks and benefits of the interferon treatment, Mr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Haines v. Kerner
404 U.S. 519 (Supreme Court, 1972)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Monell v. New York City Dept. of Social Servs.
436 U.S. 658 (Supreme Court, 1978)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
City of Canton v. Harris
489 U.S. 378 (Supreme Court, 1989)
Wilson v. Seiter
501 U.S. 294 (Supreme Court, 1991)
Hollingsworth v. Hill
110 F.3d 733 (Tenth Circuit, 1997)
Foote v. Spiegel
118 F.3d 1416 (Tenth Circuit, 1997)
Dodds v. Richardson
614 F.3d 1185 (Tenth Circuit, 2010)
Sealock v. State Of Colorado
218 F.3d 1205 (Tenth Circuit, 2000)
Oxendine v. Kaplan
241 F.3d 1272 (Tenth Circuit, 2001)
Garrett v. Stratman
254 F.3d 946 (Tenth Circuit, 2001)
Mata v. Saiz
427 F.3d 745 (Tenth Circuit, 2005)
Yu Kikumura v. Osagie
461 F.3d 1269 (Tenth Circuit, 2006)
Martinez v. Beggs
563 F.3d 1082 (Tenth Circuit, 2009)
Bacchus Industries, Inc. v. Arvin Industries, Inc.
939 F.2d 887 (Tenth Circuit, 1991)
Messerschmidt v. Millender
132 S. Ct. 1235 (Supreme Court, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Dawson v. Archambeau, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dawson-v-archambeau-cod-2020.